EMA as well as FDA recently designated PureIMS’s colistin dry powder inhaler ‘Colistin Cyclops®’ orphan drug product for the treatment of cystic fibrosis.   Colistin Cyclops® is an orally inhaled antibiotic used for treating (chronic) Pseudomonas aeruginosa infections of the lungs. Despite the transformative potential of CFTR modulators in addressing the root causes of cystic fibrosis, […]

Fagron and PureIMS have joined forces to make CYCLOPS® dry powder inhaler available nationwide in the Netherlands. The two Dutch pharmaceutical companies recently signed an agreement, granting Fagron the exclusive rights to organize the national distribution of PureIMS’s compounded preparations, such as an inhaled antibiotic for the treatment of pulmonary Pseudomonas aeruginosa infections caused by […]

Roden, the Netherlands, January 18, 2024 PureIMS, a pharmaceutical company focused on the development of innovative inhalation products, this week reported it has completed a comparative pharmacokinetic study with Levodopa Cyclops®. The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. These properties make Levodopa Cyclops® a prime candidate […]

Following a successful funding round in April of this year (link: successful funding round), PureIMS obtained ethical approval for a pharmacokinetic dose-finding study with its dry powder inhaler lead program Levodopa Cyclops™ and expects to have the study results before the end of 2023. Earlier clinical studies already demonstrated very rapid onset of action, a […]

Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases, has appointed Frank Lambert to the role of Executive Director Commercialization. DPI developer PureIMS has announced the appointment of Frank Lambert as Executive Director Commercialization. The appointment is part of the […]